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Background: Coronary heart disease (CHD) is one of the leading causes of death worldwide. Scientific literature
shows that prevention of CHD is inadequate. The clinical pharmacist’s role in patient-centred care has been shown
favourable in a large amount of studies, also in relation to reduction of risk factors related to CHD. We developed
and piloted a pharmacist-led follow-up program for patients with established CHD after hospital discharge from a
hospital in North Norway. The aim of the present study was to explore how participants in the follow-up program
experienced the program with regard to four main topics; medication knowledge, feeling of safety and comfort
with medications, the functionality of the program and the clinical pharmacist’s role in the interdisciplinary team.
Methods: We performed semi-structured thematic interviews with four patients included in the program. After
verbatim transcribing, we analysed the interviews using “qualitative content analyses” by Graneheim and Lundman.
Trial registration www.clinicaltrials.gov: NCT01131715.
Results: All participants appreciated the follow-up program because their medication knowledge had increased,
participation had made them feel safe, they were reassured about the appropriateness of their medications, and
they had become more involved in their own medication. The participants reported that the program was well
structured and the clinical pharmacist was said to be an important caretaker in the health-care system. The importance
of collaboration between pharmacists and physicians, both in hospital and primary care, was emphasized.
Conclusion: Our results indicate that the follow-up program was highly appreciated among the four participants
included in this study. The results must be interpreted in the context of the health care system in Norway today.
Here, few pharmacists are working in hospitals or in close relation to the general practitioners. In addition,
physicians are short of time in order to supply appropriate medication information, both in hospital and primary
care. Involving pharmacists in follow-up of patients with CHD seems to be highly appreciated among patients and
may be a step towards improving patient care. The study is limited by the low number of participants.
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Coronary heart disease (CHD) is one of the leading
causes of death world-wide [1]. A wealth of scientific
evidence shows that lifestyle interventions, control of
risk factors and use of cardioprotective drug therapies
can reduce the risk of recurrent nonfatal and fatal dis-
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reproduction in any medium, provided the orthis, Kotseva et al. has during three cross-European sur-
veys (EUROASPIRE I-III) showed that secondary pre-
vention of CHD is alarmingly inadequate with persistent
smoking habits, high prevalence of obesity, inadequate
control of blood pressure, lipids and blood glucose, with
most patients not achieving therapy guideline defined
targets [3]. In the wake of the EUROASPIRE surveys, a
nurse-coordinated follow-up program for patients with
CHD (EUROACTION) was initiated and rolled out as a
randomized controlled trial (RCT) in eight European
countries. Interpretations from the RCT include thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ual countries is needed in order to care for coronary and
high-risk patients [4].
A growing body of studies now indicates that involve-
ment of the clinical pharmacist in direct patient care im-
proves medical therapy and patient outcomes relevant to
secondary prevention of CHD, for example blood pres-
sure, blood lipids, prescription of cardioprotective drugs
[5-10]. Despite this, few follow-up programs for patients
with CHD described in literature, involve the clinical
pharmacist as a one of the main stakeholders. Taveira et
al. describes a Pharmacist-Led Cardiac Risk Reduction
Clinic (CRCC) in the USA, where risk reduction in
terms of Framingham risk score for CHD was reduced
in patients participating in the CRCC [11,12]. Reilly and
Cavanagh describe a successful pharmacist-nurse-run
clinic for patients with cardiovascular disease in terms of
optimizing drug and lifestyle therapy [13]. Lee et al.
showed positive effect of a pharmacy care program (FAME)
in terms of increased medication adherence, medication
persistence and clinically meaningful reductions in blood
pressure [14].
At the University Hospital in North Norway, a new
follow-up program for patients with established CHD
was developed and piloted during 2009-2011 (unpub-
lished data). The program was run by a clinical pharma-
cist. The intervention group receiving follow-up finally
included 49 patients. Few studies have explored patient
experience with pharmacist involvement in patient care,
though high satisfaction have been observed [15-20]. We
aimed to explore the experience of participating patients
in the follow-up program. We chose to use a qualitative
approach with semi-structured interviews, because ques-
tionnaires do not widely allow for elaboration of an-
swers. The study was performed by an undergraduate
masters student in Pharmacy, and formed basis for his
masters thesis in 2010 [21].
Methods
The follow-up program
Only patients with established CHD were included,
meaning patients who had a diagnosis of myocardial in-
farction, angina pectoris, coronary artery bypass graft op-
eration or coronary stent implantation. During a twelve-
month period after discharge from the Department of
Cardiology, the clinical pharmacist had consultations with
patients three times; at discharge (at the ward), after three
and twelve months (at the hospital pharmacy). The
meetings lasted 30-60 minutes and comprised medi-
ation reconciliation, medication therapy review, and pa-
tient education concerning medications and lifestyle
(physical activity, smoking cessation and heart-friendly
diet). Identified drug related problems were communi-
cated to the patients’ physician either personally (firstmeeting) or by phone or letter (the two last meetings).
After each meeting, patients received a written sum-
mary from the meeting in addition to laboratory results,
correct medication list, information about the specific
medications they were using, and individual instruc-
tions. The general practitioner (GP) received a letter
with laboratory values, identified drug-related problems
and recommendations on how to handle these.
Enrolment of participants
Participants in the follow-up program that had met with
the clinical pharmacist at least twice were eligible for in-
clusion if they were living within the city boundary of
Tromsø. Because of the limited time available for the
masters project, we aimed to include at least four to six
participants. In the period February-March 2010 the
clinical pharmacist handed out written information
about the study to eligible patients at the end of the con-
sultation. To conceal patient participation for the
pharmacist, the patients were asked to read the informa-
tion at home and to return the signed consent paper to
a third party by normal mail. A pre-paid envelope was
supplied. To avoid including more than the estimated
number of participants, the pharmacist recruited pa-
tients in blocks of four. If a sufficient number was not
included after one recruitment block, the pharmacist
was asked to repeat the procedure. The enrolment pro-
cedure was repeated four times in total, ending in March
2010 when five patients had returned their consent pa-
pers. These patients were contacted by phone and a
face-to-face interview was arranged. Participants were
free to choose whether the interview should be held in
their home or at the Department of Pharmacy (close to
the hospital). One participant withdrew before the inter-
view because of sudden illness. Finally, two males and
two females were interviewed. They were aged 47, 57, 62
and 71 years.
The interviews
A semi-structured interview guide was developed based
on four main topics:
 How did the follow-up program influence patient
knowledge about medicines?
 How did the follow-up program influence the patients’
feeling of safety and comfort with medication?
 How was the functionality of the follow-up
program?
 What did the participants think about the clinical
pharmacist’s role in the interdisciplinary health-care
team?
To begin the interviews, participants were asked the
question: “Can you tell me about the follow-up you are
Table 1 Results from ‘qualitative content analysis’ of four
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encouraged to speak freely, in order to capture the narra-
tive. The interviewer asked questions rooted in the main
topics to elaborate, clarify and confirm understanding.
Interviews were held during February and March 2010.
None of the interviewees chose to perform the interviews
at home. Interviews lasted 40-60 minutes, were audio-
taped and transcribed verbatim by the interviewer directly
afterwards. Field notes were taken. To ensure that both
the manifest and the latent content were reflected in the
narratives, the interviews were listened to several times
during the transcription phase. The narratives were subse-
quently “washed”, meaning that all sentences were struc-
tured to make sense and extra words were omitted.
Quotes were subsequently translated into English by the
principal investigator (BHG). Translation was verified by
the co-authors. To give feedback on interviewing tech-
nique and content, the whole research group read thor-
oughly through the first narrative before the next
interview was held. The whole research group read all in-
terviews before data analysis.
Data analysis
An initial analysis was performed by the master student
using the thematic approach described as ‘qualitative
content analysis’ by Graneheim and Lundman [22]. This
approach comprises the following elements: i) reading of
all texts several times in order to obtain a sense of the
whole; ii) identifying units of analysis in accordance with
the main topics and bringing these into texts; iii) identi-
fying meaning units and abstracting these into condensed
meaning units; iv) labelling the condensed meaning units
with a code; v) comparing the codes concerning similar-
ities and differences and sorting them into main-categories
and sub-categories, which constitute both the manifest
and the latent content of the interviews, vi) summarizing
the contents of the main categories to generalized descrip-
tions and experiences reflecting the most important as-
pects of each topic in the interview guideline. The same
analysis was subsequently made by the principal investiga-
tor (BHG), and validated by the research team (SLS, LS),
who agreed upon the final interpretation.
Ethics
This study has been conducted in accordance with the
principles of the Helsinki Declaration [23]. Informed con-
sents were obtained from all participants and the Regional
Committee for Medical Research Ethics North Norway
approved the study. Registration number at www.clinical-
trials.gov is NCT01131715.
Results
The four initial main topics were eventually reduced to
three topics. The topic ‘feeling of safety and comfortwith medication’ was merged with the topic ‘experiences
with the follow-up program’, based on the finding that
all four participants expressed that the program itself
had made their ‘feeling of safety and comfort with medica-
tions’ increase. In Table 1, the findings from the analysis
are shown. In the following sections, condensed versions
of the three final topics are given. The informants are re-
named Steve (62 years) , Bryan (47 years), Claire (57 years)
and Mary (71 years).Experiences with the follow-up program
Experiences with the follow-up program were found to
be characterized by its framework and execution, the
pharmacist’s performance and her empathic behaviour.
In addition, all participants said that the program had
made them feel more safe and comfortable with their
medications. These experiences were categorized into
‘specific’ and ‘abstract’ experiences, the latter category
covering feelings and personal opinions.
The informants described the follow-up program with
words like ‘great’, ‘a positive experience’, ‘educative’, that
they felt ‘safeguarded’ and ‘fortunate’, that they had ‘re-
ceived special treatment’ and ‘help in daily life’. All four
informants stated that the follow-up program should be
recommended to everybody that uses medications. Steve
suggested that everybody using medications should be
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Claire described it like this:
“You don’t get enough information about medicines.
So, you’ve really made a discovery with this program!
Everybody using medications, or at least everybody
who use medications after hospitalization, and who
has to use medications life-long, should have this kind
of follow-up” (Claire) [1]
All participants expressed that they had gained new
and clarifying information about their medication.
Claire, Mary and Bryan even believed that their medica-
tion regime had become better and more appropriate.
All participants appreciated the pharmacist’s thorough
knowledge about medications and her critical attitude
towards them, which can be explained by the general
scepticism towards medications expressed by all four
participants. In fact, It seemed like they most of all did
not want to use medications, or at least wanted to keep
them at a minimum. In addition to the pharmacist’s pro-
fessional skills, the emphatic way of acting with patients
played an important role when educating about medica-
tions. Mary said:
“She was a human being that I could talk to. One that was
professionally educated, who was skilled in supervising
me about my medications and my disease” (Mary) [2]
How the follow-up program was carried out seemed
important to the participants. The following elements
were highlighted: the generous time schedule during
follow-up, the proximity to the place where meetings
took place, and the fact that they received summary let-
ters and copies of correspondence with the GP.
Bryan and Steve also preferred personal meetings over
phone meetings. They said that it established a closer re-
lationship with the pharmacist and that they could de-
vote themselves fully to the follow-up issues without
being disturbed. Mary and Bryan also felt that the
follow-up program had been presented to them in a re-
spectful way, not ‘like a salesman’ as Bryan stated it.
Claire, Bryan and Mary also appreciated that they did
not have to keep track on so many things during follow-
up, as Bryan announced:
“If I would have to write a diary, journal or
remember anything in particular, like sending in
reports or whatever… I doubt that I would have
joined–I’m so bad in keeping track of such things”.
(Bryan) [3]
All four informants said that they felt safe when being
part of the follow-up program. The feeling of safetyseemed to be related to both the pharmacist’s profes-
sional skills as well as the predictability of the follow-up
program. The fact that the pharmacist supplied a ‘second
opinion’ about the medications, the availability of the
pharmacist by phone, and the honest answers to ques-
tions also seemed to contribute to the feeling of being
cared for. Consequently, this made participants feel safe.
That the participants felt safe while participating in this
program seemed to be related to their feeling of not be-
ing properly taken care of by the public health care sys-
tem. Claire said:
“If I had not joined this program, I would have been
all on my own” (Claire) [4]
Knowledge about medications
All participants said that they had gained knowledge
about medications in some way or another. They had in-
creased their knowledge within the following topics:
‘medication use’, ‘how to take medications’ and ‘their own
attitude towards medicines’. The latter category could be
dichotomized into the well-known principles within phar-
macy; ‘adherence’ and ‘concordance’, respectively reflecting
‘The extent to which the patient’s behaviour matches
agreed recommendations from the prescriber’ and ‘a
consultation process, in which doctor and patient agree
upon therapeutic decisions that incorporate their re-
spective views’ [24,25].
Knowledge gained by participants seemed to be founded
in the thorough and comprehensible information given by
the pharmacist, which was highlighted by all informants.
Mary stated:
“She explained in a manner so that I understood like
I’d never done before” (Mary) [5]
This shows the importance of communication skills
and communicating with patients in a language they
understand. Claire said she had become more adherent
with her medication regime, as she now recognized the
importance of her medications. Steve and Bryan said
they had become more conscious about their medication
use, which indicates a higher understanding, which is
one of the cornerstones of ‘the concordance principle’.
Everybody expressed that they had acquired specific
knowledge, either about the correct time of the day to
take medications (for example simvastatin at night in
order to obtain optimal effect), important food-drug in-
teractions (for example calcium absorption may be
inhibited by dietary fibre) or the drugs’ intended effect
(for example β-blockers to slow your heart rate). Claire
and Steve also felt they had acquired knowledge about
side effects (for example that ‘aspirin may be hard for
Garcia et al. BMC Research Notes 2014, 7:197 Page 5 of 9
http://www.biomedcentral.com/1756-0500/7/197your stomach’ and ‘simvastatin may give you muscle
pain’). For Bryan, the information from the clinical
pharmacist had made him aware that he actually had
side effects from his β-blocker:
“And it struck me as a lightening, the cause of all my
troubles. They were side effects of the medications I
was using, sweating, headache, no energy, heart rate
under 40 and very lazy…” (Bryan) [6]
Bryan also told that he previously took his medications
because his doctor told him so. The other participants
indicated similar attitudes, which is the opposite of the
‘concordance principle’. The fact that they all empha-
sized how important knowledge about medication was
indicates that they were pleased with approaching ‘con-
cordance’. Mary said:
“It’s positive to know more about what you put in
your mouth and swallow with water… and believe
that this helps for this and that. But to know why
it helps and how… that’s what I think is positive.
That you learn more about it, not just eat and
swallow what the doctor has told you to.”
(Mary) [7]The clinical pharmacist’s role in the interdisciplinary team
The participants’ experiences with the pharmacist as part
of the interdisciplinary team, was frequently expressed in
comparison with their experiences with the public health-
care service in general; the GP, the hospital and the com-
munity pharmacies. Our findings have to be seen in the
light of the Norwegian healthcare system, where patients
are not familiar with encountering clinical pharmacists.
Consequently, they compare their experience with the
follow-up program with the healthcare service they nor-
mally receive.
All four participants expressed that time with and in-
formation from their GP was inadequate. They said that
the pharmacist had been more available for questions.
Bryan called the GP system an ‘on-going industry’. His
argument was that that he always exited the physician’s
office within ten minutes after entering, including pay-
ment, feeling that the consultation is too short. Mary
thought that explanations she received from her physi-
cians were of poor quality. In fact, when the participants
spoke about their GPs, they all expressed feelings like
‘lack of confidence’, ‘not being taken seriously’ and ‘given
a prescription to end the appointment’. Seen in the light
of such experience, it is perhaps not strange that they
appreciated the pharmacist’s suggestions medication
amendments, and that they acknowledged the pharma-
cist as part of the interdisciplinary team as the oneoffering a ‘second opinion’ of their medications. Steve
said:
“I think it’s reasonable that a pharmacist has an
overview parallel to the physician’s, and perhaps also
has a different view on things” (Steve) [8]
Bryan, Claire and Mary told that their GPs had appre-
ciated and welcomed the pharmacist’s medication rec-
ommendations. Mary said that she had actually feared a
negative reaction from her GP, and indicated that GPs
might experience pharmacist involvement as interfering
with their area of expertise.
The participants regarded community pharmacies like
more or less “normal shops”, where ‘you hand in your
prescription, you pay and you leave’, as Bryan stated.
Claire said that the follow-up from the clinical pharma-
cist was something totally different and that she had
never experienced to get information from pharmacists
in a community pharmacy. She now wanted the com-
munity pharmacists to be more available and visible in
the pharmacies. Steve also felt that it would be easier to
approach community pharmacists after the follow-up
program.
The clinical pharmacist’s role in the hospital service
was acknowledged by all participants, and must also be
seen in relation with their disappointment concerning
follow-up from their hospital. Involvement from a
pharmacist at the ward was regarded as positive because
of the pharmacists’ skills within medication counselling.
Again, this must be seen in relation to the physicians’
shortage of time. Mary said:
“I think that having a pharmacist at the hospital ward
would be very good. They can explain about
medication use, because the doctors, unfortunately,
don’t have time for that” (Mary) [9]
Steve also had thoughts about ‘the Heart School’,
which is a two-day follow-up program offered by the
University Hospital of North Norway to patients that
have experienced their first myocardial infarction. The
program comprises group teaching by a cardiologist
about CHD, by a pharmacist about medications, by a
physiotherapist about physical activity and by a nutrition-
ist about diet and heart-protective food. The patients also
receive a one-to-one consultation with the cardiologist.
Steve suggested that the pharmacist should also perform
one-to-one consultations, in the same manner as the car-
diologist. He said:
“You have the physiotherapist and the expert in
nutrition. You have the cardiologist, and you have the
pharmacist. Those four are important, I believe… and
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four should form a team. The result will be a better
understanding of the relationship between
medications, diet, physical activity and stress. [….] It’s
important that the patients with coronary heart
disease get to speak with the pharmacist. This may be
feasible at the Heart School. Time for personal
consultations with the pharmacist must be a priority”
(Steve) [10]
Altogether, pharmacist collaboration with the GP and
the hospital physician were appreciated and seen as im-
portant, both to inform about mediation, and to perform
‘quality checks’ of medication regimens. Claire thought
that all patients at a cardiology ward should meet the
pharmacist before discharge. Steve was also convinced
about the economy in this; he thought this could make a
means to get patients more rapidly back to work. Con-
cerning medication dispensing at the community phar-
macy, Steve found it troublesome if he had to return to
his GP for a new prescription because the pharmacist re-
vealed a drug related problem. This indicates that medi-
cation therapy review should be performed at the time
of prescription.
Despite the positive endorsement of the pharmacists’
role in the interdisciplinary health-care team, there were
concerns raised by the participants regarding how differ-
ent tasks should be distributed between the different
members of the healthcare team. In addition, the concern
for the patient having too many healthcare professional to
relate to was also mentioned. Steve said:
“I believe the patients will benefit from the
collaboration between the physician, the pharmacist
and the nurse–if it’s done properly. However, the
patient cannot relate with too many persons. It might
not be necessary for the pharmacist to have their own
consultations with the patients at the ward, but the
physician must use the pharmacists’ knowledge more
than today… I’m sure they [the pharmacists] have
more knowledge about medicines than the physicians.
But the specific way to go forward can be
troublesome… to find the middle way.” (Steve) [11]
Discussion
Applying a thematic approach, this study is the first
study to explore experiences from patients with estab-
lished CHD with a pharmacist-led one-year follow-up
program after hospital discharge. All participants highly
appreciated the program, which is in accordance with
findings from other studies where satisfaction with
pharmacist involvement in direct patient care has been
explored [15,17,19]. Time seemed to be an important
factor for all participants, which must be seen in relationto their experience of shortage of time by healthcare
professionals in general. Tsiantou et al. also found that
time spent by pharmacist in patient relationships was as
an important factor in order to increase medication ad-
herence [18].
But time was not the only factor that contributed to
the participants’ positive experience with the follow-up
program. As also mentioned by Tsiantou et al. and
Lalonde et al., participants were interested in deeper
and more comprehensible information to increase their
understanding of their medications, as this had not been
offered by their GP’s [15,18]. All participants expressed
critical attitudes towards medications, which may be one
reason why the ‘second opinion’ from the pharmacist
seemed to be of great importance. This ‘second opinion’
had also made them feel comfortable and safe with their
medication regime. The pharmacist’s ability to identify
inappropriate prescribing and drug-related problems
through medication therapy reviews is widely recognized
and embraced by the philosophy of pharmaceutical care
[26-29]. This also corresponds to the participants’ ac-
knowledgement of the pharmacist’s involvement in quality
checking medication regimes.
Non-adherence to medications use has been shown to
be one of the most important factors for therapy failure
[30]. In our study, participants stated that they had be-
come more adherent to their medication regimes as their
level of knowledge had increased. They were also inter-
ested in taking part in decision making in relation to their
medications; not only obeying their doctors. It might seem
like adherence with the GP’s prescribing was replaced with
the principle of ‘concordance’ during the follow-up pro-
gram. However, this needs further investigation.
According to our findings, pharmacists should be in-
volved in patient care at different levels; medication in-
formation to patients, collaboration with physicians in
medication-related questions and quality check of drug
regimens (both at hospitals and in community care),
and individual medication consultations, for instance at
the ‘Heart School’. In general, pharmacists were ac-
knowledged to have more thorough knowledge about
medicines compared to physicians. In other countries,
for instance in the USA and the UK, pharmacists are
already participating in these kind of activities, which
has been shown to improve health-related outcomes
[31]. It was however surprising that the community
pharmacy were disregarded as a place for drug informa-
tion, and only acknowledged as a place for drug dis-
pensing. This is contradictory to the Norwegian legal
framework of the pharmacies, where the role concern-
ing medication information is emphasized [32]. This
perception needs further investigation, as this will be
crucial for further development of patient-centred com-
munity pharmacy services.
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cist as part of the health-care team, we need to take into
account that participants were concerned about how
the pharmacist-physician collaboration should function
without friction. The fact that pharmacists are not fully
acknowledged as part of the interdisciplinary team in
Norway today may have contributed to this finding. It
will be essential to clarify the clinical pharmacist’s role
in the healthcare team, allowing patients to know
exactly what to expect from the different health-care
personnel.
Credibility
“Credibility deals with the focus of the research and re-
fers to confidence in how well data and processes of ana-
lysis address the intended focus” [22]. In our study,
several elements need to be considered: i) The number
of informants may not have been sufficient to embrace
all aspects of the follow-up program and a larger study
may have shown more variation in findings. However,
the four main topics were explored and elaborated satis-
factory by all participants. The results of a qualitative
study cannot be generalized in the same way as in quan-
titative studies. The study has, however, shown what it
may be like to be in the follow-up program–an insight
that in itself may enrich our body of knowledge and also
initiate new research questions. ii) The interviews fo-
cused on four main topics, which is also reflected in the
findings above. The narrative approach was important,
and a semi-structured interview-guide was supposed to
allow the participants to tell their own story in their
own words. We wanted to gain knowledge concerning
the main topics, but also concerning other relevant as-
pects not covered by the main topics. We realize that
focus on the main topics may have been too strong to
allow for the latter to happen. iii) The interviews were
performed at the Department of Pharmacy. Dahlberg ar-
gues that interviews in the participants’ homes is experi-
enced as safer and more Comfortable [33]. Consequently,
we might have gained more knowledge if interviews were
performed in the participants’ home. (iv) Verbatim tran-
scribing of the interviews was done in ‘bokmål’, which was
neither spoken by the informants nor by the interviewer.
This may have introduced misunderstandings. We did try
to diminish this by listening to the text several times dur-
ing transcription. Additionally, quotes have been trans-
lated from Norwegian to English, which again may have
introduced ambiguity in interpretation. This was sought
diminished by verifying translation by several parts.
Nevertheless, some degree of interpretation cannot be
avoided because qualitative research is a product of reflex-
ivity (that fact that the researcher’s pre-understanding and
decisions will inevitable have impact upon the meaningand context of the experience under investigation between
informants, interviewer and analysing process) [34]. This
has to be interpreted by the reader in the light of our de-
scriptions. v) The second analysis was performed by the
PI, who was the clinical pharmacist during the follow-up
program. Recall bias has been minimized by concealing
patient identity and performing the second analysis more
than twelve months after the end of the follow-up pro-
gram. Nevertheless, the analysis may be biased by personal
perceptions and negative patient experiences with the
follow-up program may be concealed. Because the narra-
tives were analysed twice by different persons and vali-
dated by the research group, we have sought to diminish
also this bias.Dependability
Dependability concerns “the degree to which data change
over time and alterations made in the researcher’s deci-
sions during the analysis process” [22]. Our data com-
prised four narratives that were collected during a relative
short period of time. The time factor is not considered
crucial in relation to the content of the interviews. The
interviewer may have changed his interviewing technique
slightly from interview to interview, which is considered
one of the hallmarks of good qualitative methodology;
variability rather than standardization, also called flexibility
[34]. It is, however, important that flexibility is considered
alongside reflexivity [34]. In this case, that the interviewer
was an undergraduate pharmacist student, inexperienced
in qualitative interviewing and possibly biased by the fact
that he thought this program was positive. If the inter-
viewer for instance had a different professional background,
had more experience or was negative towards such a pro-
gram, results might have been different and other aspects
of the program may have been revealed.Transferability
Transferability refers to “the extent to which the findings
can be transferred to other settings or groups” [22]. We
only included patients with CHD, who were participants
of the follow-up program. Our results consequently re-
flect our new knowledge concerning this particular pa-
tient group and this particular follow-up program.
However, as CHD is the number one disease worldwide,
and also frequently co-morbid to other diseases, for ex-
ample diabetes, renal failure and chronic obstructive
pulmonary disease (COPD), our findings may be applic-
able also in other patient groups. However, this remains
to be explored. It is said that “the most useful indicator
of credibility of the findings is when the practitioners
themselves and the readers of the theory view the study
findings and regard them as meaningful and applicable
in terms of their experience” [35].
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We have through four semi-structured interviews gained
knowledge about how post-discharged patients with estab-
lished CHD experienced a twelve-month lasting follow-up
program managed by a clinical pharmacist. The study is
limited by the low number of participants. However, the
program was highly appreciated, mostly because partici-
pants had achieved a higher level of knowledge concern-
ing their medications, but also because their medication
regime had undergone a ‘quality check’. Our findings must
be seen in connection with the participants’ rather nega-
tive experience with their GPs, including shortage of time
and dissatisfaction with information, information quality
and follow-up. These factors most likely contributed to
their increased feeling of safety with the follow-up pro-
gram. Surprisingly, community pharmacies were not con-
sidered a place for medication information by the four
participants, which need to be further investigated, as
community pharmacies are moving into more patient-
centred care.
The clinical pharmacist was well recognized as part of
the interdisciplinary healthcare team to be involved in
medication information to patients, support for physi-
cians in medication-related questions, and also as inde-
pendent care givers. It is however important that the
role of the clinical pharmacists is clarified, in order for
patients to know what to expect from different health-
care takers. We believe our findings are not restricted to
patients with CHD only, but may apply also to other pa-
tient populations; though further research is needed. Fi-
nally, we encourage pharmacists to continue focusing on
patient-centred care, and physicians to increase their
collaboration with pharmacists in medication-related
questions. This seems to be highly appreciated among
patients and may be a step towards improving patient
care.
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